Cara Therapeutics files investor presentation for proposed merger with Tvardi

Tvardi Therapeutics, Inc.

Furnishes investor presentation (Exhibit 99.1) for post-combination company with Tvardi, a STAT3-targeted fibrosis biopharma.
Merger announced Dec 17, 2024; pending regulatory and shareholder approvals; S-4 filed with preliminary proxy/prospectus.
Presentation is being shared with potential investors; no new financial terms or deal value disclosed in filing.
Forward-looking statements reference efforts to regain Nasdaq compliance on stockholders' equity requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.